文献速递垂体与肾上腺疾病

原发性醛固酮增多症患者治疗后动脉僵硬度逆转中盐皮质激素受体活性的意义

Implication of MR Activity in Posttreatment Arterial Stiffness Reversal in Patients With Primary Aldosteronism.
PubMed 文献 · J Clin Endocrinol Metab · 2023-01-01

该研究前瞻性纳入445例原发性醛固酮增多症患者,比较手术与药物治疗后动脉僵硬度的逆转情况。结果显示,肾上腺切除组和药物治疗后血浆肾素活性未抑制(≥1.5 ng/mL/h)组治疗后脉搏波速度显著改善(均P < .001),而肾素活性抑制组无显著改善(P = .151)。

要点

  • 肾上腺切除组和MRA治疗后PRA未抑制组PWV显著改善,PRA抑制组无显著改善。
  • MRA治疗患者中,治疗后PRA 1.5 ng/mL/h为预测PWV改善的最佳切点。
  • MRA治疗患者中,log转换的治疗后PRA、年龄和基线PWV与ΔPWV独立相关。

核心结论

  • 在肾上腺切除的PA患者和药物治疗后PRA未抑制的PA患者中观察到动脉僵硬度逆转。

研究设计与样本

  • 前瞻性纳入445例原发性醛固酮增多症患者,收集治疗前和治疗后12个月的临床特征、生化、血压和脉搏波速度数据。
  • 255例接受肾上腺切除(组1),190例接受MRA治疗;MRA治疗者根据治疗后PRA分为抑制组(<1.5 ng/mL/h,组2)和未抑制组(≥1.5 ng/mL/h,组3)。

主要发现

  • 仅组1和组3患者治疗后PWV有统计学显著改善(均P < .001),组2治疗后无显著改善(P = .151)。
  • 方差分析和事后分析中,组2的ΔPWV显著低于组1(P = .007)和组3(P = .031)。
  • MRA治疗患者的多因素回归分析确定log转换的治疗后PRA、年龄和基线PWV为ΔPWV的独立相关因素。

关键数值与推荐

  • RCS模型显示治疗后PRA 1.5 ng/mL/h为最佳切点值。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Primary aldosteronism (PA) patients have a higher degree of arterial stiffness, which can be reversed after adrenalectomy. OBJECTIVE: We aimed to compare the reversal of arterial stiffness between surgically and medically treated PA patients and to identify the predictors of effective medical treatment. METHODS: We prospectively enrolled 445 PA patients and collected data on baseline clinical characteristics, biochemistry, blood pressure, and pulse wave velocity (PWV) before treatment and 12 months after treatment. In the mineralocorticoid receptor antagonist (MRA)-treated patients, the relationship between the change in PWV after 1 year (ΔPWV) and posttreatment renin activity was explored using the restricted cubic spline (RCS) method. RESULTS: Of the 445 enrolled PA patients, 255 received adrenalectomy (group 1) and 190 received MRAs. In the RCS model, posttreatment plasma renin activity (PRA) 1.5 ng/mL/h was the best cutoff value. Therefore, we divided the MRA-treated patients into 2 groups: those with suppressed PRA (< 1.5 ng/mL/h, group 2), and those with unsuppressed PRA (≥ 1.5 ng/mL/h, group 3). Only group 1 and group 3 patients had a statistically significant improvement in PWV after treatment (both P < .001), whereas no significant improvement was noted in group 2 after treatment (P = .151). In analysis of variance and post hoc analysis, group 2 had a significantly lower ΔPWV than group 1 (P = .007) and group 3 (P = .031). Multivariable regression analysis of the MRA-treated PA patients identified log-transformed posttreatment PRA, age, and baseline PWV as independent factors correlated with ΔPWV. CONCLUSION: The reversal of arterial stiffness was found in PA patients receiving adrenalectomy and in medically treated PA patients with unsuppressed PRA.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Chen ZW, Pan CT, Liao CW, et al. Implication of MR Activity in Posttreatment Arterial Stiffness Reversal in Patients With Primary Aldosteronism. J Clin Endocrinol Metab. 2023. PMID: 36333943. doi:10.1210/clinem/dgac649

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。